| Literature DB >> 32920979 |
Evelina Miele1, Agnese Po2, Angela Mastronuzzi1, Andrea Carai3, Zein Mersini Besharat4, Natalia Pediconi5, Luana Abballe4, Giuseppina Catanzaro4, Claudia Sabato4, Enrico De Smaele4, Gianluca Canettieri2, Lucia Di Marcotullio2, Alessandra Vacca4, Antonello Mai6, Massimo Levrero7,8, Stefan M Pfister9,10,11, Marcel Kool9,11, Felice Giangaspero12,13, Franco Locatelli1,14, Elisabetta Ferretti4.
Abstract
Persistent mortality rates of medulloblastoma (MB) and severe side effects of the current therapies require the definition of the molecular mechanisms that contribute to tumor progression. Using cultured MB cancer stem cells and xenograft tumors generated in mice, we show that low expression of miR-326 and its host gene β-arrestin1 (ARRB1) promotes tumor growth enhancing the E2F1 pro-survival function. Our models revealed that miR-326 and ARRB1 are controlled by a bivalent domain, since the H3K27me3 repressive mark is found at their regulatory region together with the activation-associated H3K4me3 mark. High levels of EZH2, a feature of MB, are responsible for the presence of H3K27me3. Ectopic expression of miR-326 and ARRB1 provides hints into how their low levels regulate E2F1 activity. MiR-326 targets E2F1 mRNA, thereby reducing its protein levels; ARRB1, triggering E2F1 acetylation, reverses its function into pro-apoptotic activity. Similar to miR-326 and ARRB1 overexpression, we also show that EZH2 inhibition restores miR-326/ARRB1 expression, limiting E2F1 pro-proliferative activity. Our results reveal a new regulatory molecular axis critical for MB progression.Entities:
Keywords: ARRB1; E2F1; EZH2; medulloblastoma; miR-326
Mesh:
Substances:
Year: 2020 PMID: 32920979 PMCID: PMC7858128 DOI: 10.1002/1878-0261.12800
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 7.449